<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2060">
  <stage>Registered</stage>
  <submitdate>23/07/2008</submitdate>
  <approvaldate>23/07/2008</approvaldate>
  <nctid>NCT00722046</nctid>
  <trial_identification>
    <studytitle>Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease</studytitle>
    <scientifictitle>A Phase 2 Multicenter, Randomized, Double Blind, Placebo-Controlled Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A9951002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - PF-04360365 0.1 mg/kg
Other interventions - PF-04360365 0.5 mg/kg
Other interventions - PF-04360365 1 mg/kg
Treatment: drugs - Placebo
Other interventions - PF-04360365 3 mg/kg
Other interventions - PF-04360365 8.5 mg/kg

Experimental: PF-04360365 0.1 mg/kg - 

Experimental: PF-04360365 0.5 mg/kg - 

Experimental: PF-04360365 1 mg/kg - 

Placebo Comparator: Placebo - 

Experimental: PF-04360365 3 mg/kg - 

Experimental: PF-04360365 8.5 mg/kg - 


Other interventions: PF-04360365 0.1 mg/kg
0.1 mg/kg every 60 days (10 doses total)

Other interventions: PF-04360365 0.5 mg/kg
0.5 mg/kg every 60 days (10 doses total)

Other interventions: PF-04360365 1 mg/kg
1 mg/kg every 60 days (10 doses total)

Treatment: drugs: Placebo
Placebo every 60 days (10 doses total)

Other interventions: PF-04360365 3 mg/kg
3 mg/kg every 60 days (10 doses total)

Other interventions: PF-04360365 8.5 mg/kg
8.5 mg/kg every 60 days (10 doses total)

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety/tolerability of PF-04360365 in subjects with mild to moderate Alzheimer's disease dosed for 18 months. (adverse events, physical/neurologic exams, vital signs, 12-lead ECG, clinical labs, brain MRI, cognitive assessments)</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of PF-04360365 following administration of multiple doses in subjects with mild to moderate Alzheimer's disease. (plasma and cerebrospinal fluid (as available) PF-04360365 concentrations)</outcome>
      <timepoint>24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog); Disability Assessment for Dementia (DAD); plasma/CSF Abeta; CSF tau and phosphotau; CSF protein, RBCs, WBCs and glucose; Immunogenicity (anti-drug antibodies)</outcome>
      <timepoint>24 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Males or females of non childbearing potential, age &gt; or = 50

          -  Diagnosis of probable Alzheimer's disease, consistent with criterial from both:

               -  National Institute of Neurological and Communicable Disease and Stroke and
                  Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)

               -  Diagnostic and Statistical Manual of Mental Disorders (DSM IV)

          -  Mini-mental status exam score of 16-26 inclusive

          -  Rosen-Modified Hachinski Ischemia Score of &lt; or = 4</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Diagnosis or history of other demential or neurodegenerative disorders

          -  Diagnosis or history of clinically significant cerebrovascular disease

          -  Specific findings on magnetic resonance imaging (MRI); cortical infarct, micro
             hemorrhage, multiple white matter lacunes, extensive white matter abnormalities

          -  History of autoimmune disorders

          -  History of allergic or anaphylactic reactions</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>198</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Pfizer Investigational Site - Adelaide</hospital>
    <hospital>Pfizer Investigational Site - Woodville South</hospital>
    <hospital>Pfizer Investigational Site - Heidelberg West</hospital>
    <hospital>Pfizer Investigational Site - Nedlands</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5011 - Woodville South</postcode>
    <postcode>3084 - Heidelberg West</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Antwerpen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Edegem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Jette</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wiltshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Purpose of the study is to determine whether multiple dose administration of PF-04360365 is
      safe and well tolerated in patient with mild to moderate Alzheimer's disease.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00722046</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>